In Allergic Rhinitis and Urticaria
Adis Drug Profile
First Online: 06 January 2012 DOI:
10.2165/11209310-000000000-00000 Cite this article as: Carter, N.J. Drugs (2012) 72: 1257. doi:10.2165/11209310-000000000-00000 Abstract
Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhino-conjunctivitis and urticaria.
In two well designed phase III trials, 14 days’ treatment with bilastine was associated with a significantly lower area under the effect curve (AUEC) for the reflective total symptom score (TSS) than placebo in patients with symptomatic seasonal allergic rhinitis.
Additionally, reflective nasal symptom scores were significantly lower in bilastine than placebo recipients in patients with a history of seasonal allergic rhinitis who were challenged with grass pollen allergen in a single-centre, phase II study.
Neither bilastine nor cetirizine was effective in the treatment of perennial allergic rhinitis with regard to the mean AUEC for reflective TSS in another well designed phase III trial. However, results may have been altered by differences in some baseline characteristics and placebo responses between study countries.
In another well designed phase III trial, compared with placebo, bilastine was associated with a significantly greater change from baseline to day 28 in the mean reflective daily urticaria symptom score in patients with chronic urticaria.
There were no significant differences in primary endpoint results between bilastine and any of the active comparators used in these trials (i.e. cetirizine, levocetirizine and desloratadine).
Bilastine was generally well tolerated, with a tolerability profile that was generally similar to that of the other second-generation antihistamines included in phase III clinical trials.
Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl. 1): s147–334
Pawankar R, Canonica GW, Holgate ST, et al. World Allergy Organization white book on allergy 2011–2012:executive summary [online]. Available from URL:
[Accessed 2012 Mar 14]
Wedi B. Urticaria. J Dtsch Dermatol Ges 2008 Apr; 6 (4): 306–17
Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128 (6): 1139–50
Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA
LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64 (10): 1427–43
Golan DE, Tashjian AH Jr, Armstrong EJ, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Versailles (KY): Lippincott Williams & Wilkins, 2008
Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–76
Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007 Feb; 24 (2): 318–27
Chen C, Hanson E, Watson JW, et al. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003 Mar; 31 (3): 312–8
Lieberman P. Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc 2009; 30 (5): 482–6
Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10 (5): 779–93
A. Menarini Pharma UK. Ilaxten® (bilastine) 20 mg tablets: UK summary of product characteristics [online]. Available from URL:
[Accessed 2012 Mar 23]
Faes Farma. Bilastine (Bilaxten): Spanish summary of product characteristics [online]. Available from URL:
[Accessed 2012 Mar 27]
Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H
receptor antagonist. Drugs R D 2005; 6 (6): 371–84
Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H
receptor antagonist. Drugs R D 2006; 7 (4): 219–31
Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011; 60 (12): 1107–12
García-Gea C, Martinez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H
antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008 Dec; 28 (6): 675–85
Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009; 48 (8): 543–54
Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39 (9): 1338–47
Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64 (1): 158–65
Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65 (4): 516–28
Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhino-conjunctivitis and urticaria. Allergy 2010; 65 Suppl. 93: 1–13
Conen S, Theunissen EL, Van Oers ACM, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011 Nov; 25 (11): 1517–23
García-Gea C, Clos S, Antonijoan RM, et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects [abstract no. EC13]. Basic Clin Pharmacol Toxicol 2006; 99 Suppl. 1: 30
Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol. Epub 2011 Jun 3
Graff C, Struijk JJ, Kanters JK, et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig 2012; 32 (5): 339–51
Crean CS, Roupe KR, Sologuren A, et al. The pharmacokinetics of bilastine after single and 14 days once daily administration [abstract no. P252]. Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1: 148
Gonzalo A, Lucero ML, Orjales A, et al. Identification of processes involved in bilastine bioavailability in rats [abstract no. 69]. 10th European ISSX Meeting; 2008 May 18–21; Vienna
Sologuren A, Lucero ML, Valiente R, et al. Human mass balance with [
14C]-bilastine following oral administration to healthy volunteers [abstract no. TP85]. Basic Clin Pharmacol Toxicol 2009; 105 Suppl. 1: 106–7
Sastre J, Mullol J, Valero A, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28 (1): 121–30
Horak F, Zieglmayer P, Zieglmayer R, et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59 (5): 391–8
Montoro J, del Cuvillo A, Jáuregui I, et al. Bilastine and the central nervous system: incidence of somnolence [abstract no. 926]. Allergy 2011; 66 Suppl. 94: 358
© Springer International Publishing AG 2012